Trial Outcomes & Findings for Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC (NCT NCT00880334)

NCT ID: NCT00880334

Last Updated: 2018-09-18

Results Overview

PFS based on the Kaplan-Meier method is defined as the time between randomization and documented disease progression (PD) per RECIST 1.0 criteria or death, or is censored at time of last disease assessment. Per RECIST 1.0 for target lesions, PD is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or appearance of new lesions. For non-target lesions, PD is the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 149 participants
• Primary outcome timeframe: Disease evaluations occurred at week 6 and 12 and thereafter every 3 cycles/9 weeks on treatment and every 3 months in follow-up. Participants were followed until PD, death or lost to follow-up. Median survival follow-up was 12 months (range 1-26).
• Results posted on: 2018-09-18

Participant Flow

Patients enrolled from February 2007 through May 2010.

There were 7 cancelled patients who were randomized but did not receive treatment.

Participant milestones

Measure	Vandetanib and Docetaxel Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day Eligible participants were allowed to crossover to single agent vandetanib.
Randomized Phase STARTED	74	75
Randomized Phase Eligible & Treated	70	72
Randomized Phase COMPLETED	70	35
Randomized Phase NOT COMPLETED	4	40
Crossover Phase STARTED	0	37
Crossover Phase COMPLETED	0	37
Crossover Phase NOT COMPLETED	0	0

Reasons for withdrawal

Measure	Vandetanib and Docetaxel Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day Eligible participants were allowed to crossover to single agent vandetanib.
Randomized Phase Physician Decision	1	0
Randomized Phase Withdrawal by Subject	2	1
Randomized Phase Inadequate Labs	1	1
Randomized Phase Brain Metastasis	0	1
Randomized Phase Crossover Participants	0	37

Baseline Characteristics

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Baseline characteristics by cohort

Measure	Vandetanib & Docetaxel n=70 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day	Total n=142 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	32 Participants n=5 Participants	39 Participants n=7 Participants	71 Participants n=5 Participants
Age, Categorical >=65 years	38 Participants n=5 Participants	33 Participants n=7 Participants	71 Participants n=5 Participants
Sex: Female, Male Female	22 Participants n=5 Participants	23 Participants n=7 Participants	45 Participants n=5 Participants
Sex: Female, Male Male	48 Participants n=5 Participants	49 Participants n=7 Participants	97 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	3 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants
Race (NIH/OMB) White	61 Participants n=5 Participants	67 Participants n=7 Participants	128 Participants n=5 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	3 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants

PRIMARY outcome

Timeframe: Disease evaluations occurred at week 6 and 12 and thereafter every 3 cycles/9 weeks on treatment and every 3 months in follow-up. Participants were followed until PD, death or lost to follow-up. Median survival follow-up was 12 months (range 1-26).

Population: The analysis dataset is comprised of all eligible and treated patients.

PFS based on the Kaplan-Meier method is defined as the time between randomization and documented disease progression (PD) per RECIST 1.0 criteria or death, or is censored at time of last disease assessment. Per RECIST 1.0 for target lesions, PD is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or appearance of new lesions. For non-target lesions, PD is the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Outcome measures

Measure	Vandetanib and Docetaxel n=70 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 Participants Placebo orally and docetaxel intravenously Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day
Median Progression-Free Survival (PFS)	2.56 months Interval 1.81 to 3.06	1.58 months Interval 1.48 to 3.09

SECONDARY outcome

Timeframe: Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Median treatment duration for this study cohort approximated 2 cycles (range 1-31).

Population: The analysis dataset is comprised of all eligible and treated patients.

Grade 3-5 toxicity rate is the percentage of participants experiencing maximum grade of all toxicity types of grade 3-5 with any attribution on treatment during the randomized phase.

Outcome measures

Measure	Vandetanib and Docetaxel n=70 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 Participants Placebo orally and docetaxel intravenously Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day
Grade 3-5 Toxicity Rate	73 percentage of participants Interval 61.0 to 83.0	57 percentage of participants Interval 45.0 to 69.0

SECONDARY outcome

Timeframe: Off treatment, patients were followed for survival information every 6 months (±1 month) until death,up to 2 years after discontinuing therapy, or until lost to follow-up. Median survival follow-up for the study cohort was 12 months (95% CI: 9-18 months).

Population: The analysis dataset is comprised of all eligible and treated patients.

Overall survival is defined from date of randomization to date of death or censored at the date the patient was last known alive.

Outcome measures

Measure	Vandetanib and Docetaxel n=70 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 Participants Placebo orally and docetaxel intravenously Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day
Median Overall Survival	5.85 months Interval 5.22 to 7.0	7.03 months Interval 5.19 to 10.41

SECONDARY outcome

Timeframe: Disease evaluations occurred at week 6 and 12 and thereafter every 3 cycles/9 weeks on treatment. Median treatment duration for this study cohort approximated 2 cycles (range 1-31).

Population: The analysis dataset is comprised of all eligible and treated patients.

Objective response rate is defined as the percentage of participants who achieved a confirmed overall partial response (PR) or complete response (CR) using RECIST criteria on treatment during the randomized phase. Patients without measurable disease only at baseline are included, based on status of non-target lesions.Per RECIST 1.0 for target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no fewer than 4 weeks after the response criteria are first met. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

Outcome measures

Measure	Vandetanib and Docetaxel n=70 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 Participants Placebo orally and docetaxel intravenously Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day
Objective Response Rate	7.1 percentage of participants Interval 2.4 to 15.9	11.1 percentage of participants Interval 4.9 to 20.8

POST_HOC outcome

Timeframe: Disease evaluations occurred at week 6 and 12 and thereafter every 3 cycles/9 weeks on treatment. Median treatment duration for this study cohort approximated 2 cycles (range 1-31).

Disease control rate is defined as the percentage of participants with confirmed overall Stable Disease (SD) or better using RECIST 1.0 criteria which parallels absence of disease progression (PD) on treatment during the randomized phase. Per RECIST 1.0 for target lesions, PD is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or appearance of new lesions. For non-target lesions, PD is the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Patients without measurable disease only at baseline are included, based on status of non-target lesions.

Outcome measures

Measure	Vandetanib and Docetaxel n=70 Participants Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 Participants Placebo orally and docetaxel intravenously Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day
Disease Control Rate	51 percentage of participants Interval 39.0 to 64.0	42 percentage of participants Interval 30.0 to 54.0

Adverse Events

Vandetanib and Docetaxel

Serious events: 42 serious events

Other events: 22 other events

Deaths: 0 deaths

Placebo and Docetaxel

Serious events: 26 serious events

Other events: 12 other events

Deaths: 0 deaths

Placebo and Docetaxel-Crossover

Serious events: 6 serious events

Other events: 5 other events

Deaths: 0 deaths

Serious adverse events

Measure	Vandetanib and Docetaxel n=70 participants at risk Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 participants at risk Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day	Placebo and Docetaxel-Crossover n=37 participants at risk Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day
Immune system disorders Allergic reaction	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Anorexia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Back, pain	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Creatinine	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Dehydration	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Psychiatric disorders Depression	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Diarrhea w/o prior colostomy	7.1% 5/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Respiratory, thoracic and mediastinal disorders Dyspnea	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	5.4% 2/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Erythema multiforme	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Esophagitis	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Fatigue	8.6% 6/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	5.6% 4/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	5.4% 2/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Blood and lymphatic system disorders Febrile neutropenia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.8% 2/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders GI-other	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Blood and lymphatic system disorders Hemoglobin	4.3% 3/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hyperglycemia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Vascular disorders Hypertension	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hyponatremia	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hypophosphatemia	7.1% 5/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	4.2% 3/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection Gr0-2 neut, bladder	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection Gr 0-2 neut, blood	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection Gr0-2 neut, lung	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection w/ gr 3-4 neut, blood	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection w/ gr3-4 neut, lung	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection w/ unk ANC bladder	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection w/ unk ANC peritoneal cavity	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Joint, pain	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Leukocytes	7.1% 5/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	9.7% 7/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Lymphopenia	5.7% 4/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Muscle, pain	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Neuropathy-sensory	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Neutrophils	14.3% 10/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	13.9% 10/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Nonneuropathic generalized weakness	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Photosensitivity	4.3% 3/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations PTT	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Respiratory, thoracic and mediastinal disorders Pulmonary/Upper Respiratory-other	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations QTc interval	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Rash/desquamation	7.1% 5/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Rash: acne/acneiform	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Skin-other	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Syncope	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Vascular disorders Thrombosis/thrombus/embolism	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Ulceration	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Renal and urinary disorders Urinary frequency/urgency	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Renal and urinary disorders Urinary retention	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Injury, poisoning and procedural complications Vascular access,Thrombosis/embolism	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Vomiting	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection Gr0-2 neut, urinary tract	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Nausea	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Renal and urinary disorders Urinary hemorrhage NOS	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.

Other adverse events

Measure	Vandetanib and Docetaxel n=70 participants at risk Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day	Placebo and Docetaxel n=72 participants at risk Docetaxel: Given intravenously on Day 1 of each 21-day cycle Placebo: Taken orally once a day every day	Placebo and Docetaxel-Crossover n=37 participants at risk Docetaxel: Given intravenously on Day 1 of each 21-day cycle Vandetanib: taken orally once a day, every day
Gastrointestinal disorders Abdomen, pain	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Alkaline phosphatase	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Alopecia	4.3% 3/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Anorexia	4.3% 3/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Cardiac disorders Atrial fibrillation	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Cardiac disorders Atrial flutter	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Bilirubin	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Respiratory, thoracic and mediastinal disorders Bronchopulmonary, hemorrhage	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Constitutional, other	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Dehydration	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Diarrhea w/o prior colostomy	8.6% 6/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Dizziness	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Eye disorders Dry eye syndrome	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Dry skin	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Dyspepsia	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Dysphagia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Edema head and neck	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Edema limb	4.3% 3/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Edema trunk/genital	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Erythema multiforme	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Extremity-limb, pain	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Fatigue	12.9% 9/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	8.3% 6/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	8.1% 3/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Blood and lymphatic system disorders Febrile neutropenia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Fever w/o neutropenia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Flatulence	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Vascular disorders Flushing	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders GI-other	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Head/headache	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Blood and lymphatic system disorders Hematologic-other	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Blood and lymphatic system disorders Hemoglobin	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hyperglycemia	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hyperkalemia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Vascular disorders Hypertension	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hypoalbuminemia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hypokalemia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hypomagnesemia	5.7% 4/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Metabolism and nutrition disorders Hyponatremia	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection Gr0-2 neut, oral cavity	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection w/ gr3-4 neut, bladder	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Infections and infestations Infection w/ unk ANC skin (cellulitis)	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Psychiatric disorders Insomnia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Joint, pain	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Leukocytes	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations Lymphopenia	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Muco/stomatitis by exam, oral cavity	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Muco/stomatitis by exam, stomach	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Muscle, pain	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Nail changes	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Gastrointestinal disorders Nausea	5.7% 4/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	4.2% 3/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Neurologic-other	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Neuropathy-motor	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Neuropathy-sensory	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.8% 2/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Nonneuropathic generalized weakness	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Nonneuropathic lower extr muscle weak	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Cardiac disorders Palpitations	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Reproductive system and breast disorders Pelvic, pain	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Photosensitivity	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Pruritus/itching	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Renal and urinary disorders Proteinuria	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Rash/desquamation	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Rash: acne/acneiform	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Renal and urinary disorders Renal failure	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Respiratory, thoracic and mediastinal disorders Respiratory tract hemorrhage NOS	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
General disorders Rigors/chills	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Skin and subcutaneous tissue disorders Skin-other	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Taste disturbance	4.3% 3/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	1.4% 1/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Nervous system disorders Tremor	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Renal and urinary disorders Urinary hemorrhage NOS	2.9% 2/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Eye disorders Vision-blurred	1.4% 1/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations AST, SGOT	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Investigations ALT, SGPT	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Vascular disorders Hemorrhage-other	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Musculoskeletal and connective tissue disorders Musculoskeletal/soft tissue-other	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.
Respiratory, thoracic and mediastinal disorders Pulmonary/Upper Respiratory-other	0.00% 0/70 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	0.00% 0/72 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.	2.7% 1/37 • Assessed each cycle throughout treatment on the randomized and crossover phases from time of first dose and up to day 30 post-treatment. Median treatment duration for the randomized study cohort was 2 cycles (range 1-31 cycles). Median treatment duration for the crossover study cohort was 2 cycles (range 1-23 cycles). Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with vandetanib treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with vandetanib treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3. No further data is available to specify classification of other beyond the general term.

Additional Information

Toni Choueiri, MD

Dana-Farber Cancer Institute

Phone: 617-632-5456

Email: toni_choueiri@dfci.harvard/edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place